Pharma-Bio Serv Announces Special Dividend
Pharma-Bio Serv (OTCQB:PBSV) announced a Special Dividend of $0.075 per share for its shareholders, payable on or about January 3, 2022. This dividend will benefit shareholders of record as of the close of business on December 15, 2021. The company specializes in regulatory, compliance, and project management consulting for the pharmaceutical and biotechnology sectors, operating in markets including Puerto Rico, the U.S., Europe, and Latin America. Pharma-Bio Serv continues to emphasize its commitment to providing quality consulting services amidst ongoing industry challenges.
- Approval of a Special Dividend of $0.075 per share enhances shareholder value.
- The dividend payment reflects company confidence and financial health.
- None.
DORADO, PUERTO RICO / ACCESSWIRE / November 15, 2021 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a regulatory, compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, food and allied products industries, today announced that the Board of Directors approved a Special Dividend of
About Pharma-Bio Serv, Inc.
Pharma-Bio Serv services the Puerto Rico, United States, Europe and Latin America markets. Pharma-Bio Serv's core business is FDA and international agencies regulatory compliance consulting related services. The Company's global team includes leading engineering and life science professionals, quality assurance managers and directors.
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which statements may include information regarding the plans, intentions, expectations, future financial performance, or future operating performance of Pharma-Bio Serv. Forward-looking statements are based on the expectations, estimates, or projections of management as of the date of this news release. Although Pharma-Bio Serv's management believes these expectations, estimates, or projections to be reasonable as of the date of this news release, forward-looking statements are inherently subject to significant business risks, economic uncertainties, including any impacts of the coronavirus (COVID-19) pandemic, and competitive uncertainties, or other contingencies, which could cause its actual results or performance to differ materially from what may be expressed or implied in the forward-looking statements. Important factors that could cause Pharma-Bio Serv's actual results or performance to differ materially from the forward-looking statements include those set forth in the "Risk Factors" section of Pharma-Bio Serv's Annual Report on Form 10-K for the year ended October 31, 2020, and in its other filings with the Securities and Exchange Commission, which filings are available on www.sec.gov. Pharma-Bio Serv disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events and circumstances, except to the extent required by applicable law.
Company Contact:
Pedro J. Lasanta
Chief Financial Officer
787 278 2709
SOURCE: Pharma-Bio Serv, Inc.
View source version on accesswire.com:
https://www.accesswire.com/672735/Pharma-Bio-Serv-Announces-Special-Dividend
FAQ
What is the Special Dividend amount for PBSV?
When will the Special Dividend be paid?
Who qualifies for the Special Dividend from PBSV?
What markets does Pharma-Bio Serv operate in?
